The grants were awarded in recognition of its two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon(R) adjuvant.
Antigenics said that AG-707 is an off-the-shelf therapeutic vaccine for the treatment of genital herpes, which is caused by the herpes simplex virus-2 (HSV-2), and is based on Antigenics’ heat shock protein (HSP) platform technology.
In a four-arm, Phase 1 study, all patients who were evaluable for immune response and received AG-707 with QS-21 showed a statistically significant CD4+ T cell response (100%; 7/7) to HSV-2 antigens, and the majority of those patients demonstrated a CD8+ T cell response (63%; 5/8).